增强乳腺X线摄影在高危女性乳腺癌筛查中首次与后续筛查对比
结果显示两组癌症检出率无显著差异,后续筛查特异度更高(91.5% vs 83.4%)。研究提示CEM在后续筛查中仍可检出乳腺癌且假阳性更少。
要点
- 后续CEM筛查特异度较基线筛查更高,可减少不必要的召回和活检。
- 单纯对比增强检出癌症的比例在首次与后续筛查中相近(约60%)。
- 低能图像阴性时仍需评估重组增强图像上的强化灶。
核心结论
- CEM在发病率筛查中仍具有癌症检出价值,且特异度较患病率筛查有所提高。
- 首次筛查与后续筛查的癌症检出率和增量癌症检出率无统计学显著差异。
研究设计与样本
- 依据近3年内无乳腺癌MRI或无既往CEM定义为患病率筛查,其余为发病率筛查。
- 恶性参照标准为活检结果,良性参照标准为活检阴性或1年内影像随访阴性。
- 使用广义估计方程模型估算P值。
关键影像表现/征象
- 单纯对比增强(低能图像阴性、重组图像见强化)检出患病率筛查中30例癌症中的18例。
- 单纯对比增强检出发病率筛查中62例癌症中的36例。
- 低能图像阴性时重组图像上的强化是增量癌症检出的关键征象。
诊断标准与关键数值
- 患病率筛查癌症检出率为每1000次筛查19例癌症,发病率筛查为每1000次11.6例。
- 患病率筛查增量癌症检出率为每1000次11.4例,发病率筛查为每1000次6.7例。
- 发病率CEM特异度为91.5%(95% CI: 90.7, 92.2),患病率CEM为83.4%(95% CI: 81.6, 85.4),P = .008。
- 发病率CEM准确度为91.4%(95% CI: 90.6, 92.2),患病率CEM为83.5%(95% CI: 81.7, 85.4),P = .01。
- 癌症检出率差异P = .65,增量癌症检出率差异P = .10。
临床应用与阅片要点
- 阅片时低能图像阴性不能排除癌症,必须评估重组图像上的强化。
- 后续筛查中CEM特异度提高有助于降低假阳性召回。
- 对既往有CEM或MRI检查的高危女性,CEM随访可用于发现强化新灶。
局限性
- 回顾性单中心设计。
- 良性参照标准包括1年影像随访阴性,可能漏诊生长缓慢的癌症。
- 未报告操作者经验和阅片流程差异对结果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Studies have reported the value of contrast-enhanced mammography (CEM) for screening women at increased risk for breast cancer, based on prevalence ("baseline") screening. Purpose To compare the performance of CEM between prevalence and incidence screens in women at increased risk for breast cancer. Materials and Methods This retrospective study included CEM screens from January 2015 through December 2021. Screens were categorized as prevalence if there was no prior breast MRI in the past 3 years or no prior CEM; all others were incidence screens. Performance metrics, including cancer detection rate (CDR), incremental CDR (cancers found through enhancement on recombined images with negative low-energy [26-30 kVp] images), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, were compared between prevalence and incidence screens. Reference standards for malignant and benign results were biopsy or negative imaging follow-up in 1 year. P values were estimated using a generalized estimating equation model. Results Of 6911 screens in 2756 women (median age, 52 years [IQR, 46-58 years]), 1575 (22.8%) were prevalence screens and 5336 (77.2%) were incidence screens. Adjusting for the number of screens per individual, there was no evidence of a difference in CDR between prevalence and incidence screens (19 cancers per 1000 prevalence screens vs 11.6 cancers per 1000 incidence screens; P = .65) or in incremental CDR (11.4 per 1000 prevalence screens vs 6.7 per 1000 incidence screens; P = .10). Incidence CEM had higher specificity than prevalence CEM (91.5% [95% CI: 90.7, 92.2] vs 83.4% [95% CI: 81.6, 85.4]; P = .008), and higher accuracy (91.4% [95% CI: 90.6, 92.2] vs 83.5% [95% CI: 81.7, 85.4]; P = .01). Contrast enhancement alone helped detect 18 of 30 (60%) cancers during prevalence screening and 36 of 62 (58%) during incidence screening. Conclusion CEM continues to help detect cancers during incidence screening with improved specificity compared with prevalence screens. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Freitas in this issue.
引用
- Lee, Amir, Sevilimedu, et al. Contrast-enhanced Mammography for Breast Cancer Screening in Women at Increased Risk: Comparison of Prevalence and Incidence Screens. Radiology. 2026. PMID: 42517765. doi:10.1148/radiol.252433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。